GSK

GSK Plc Form 6-K Summary

Business Context and Reporting Period

This Form 6-K filing by GSK Plc, dated June 21, 2024, serves as a transaction notification for Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). The filing details specific share transactions executed on June 20, 2024, on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS).

Key Financial Metrics

The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on individual insider trading activities. The transaction prices observed were:

• Ordinary Shares (GB00BN7SWP63): Purchased at approximately £16.1350 to £16.1453 per share.
• American Depositary Shares (US37733W2044): Purchased at $40.7649 per ADS.

Material Changes and Transaction Details

The filing reports the following specific transactions by directors and executives:

• Wendy Becker (Independent Non-Executive Director): Purchased 446 Ordinary Shares at £16.1350 on XLON.
• Elizabeth (Liz) McKee Anderson (Independent Non-Executive Director): Purchased 225 ADSs at $40.7649 on XNYS.
• Charles Bancroft (Senior Independent Non-Executive Director): Purchased 1,811 ADSs at $40.7649 on XNYS.
• Dr. Hal Barron (Non-Executive Director): Purchased 224 ADSs at $40.7649 on XNYS.
• Dr. Anne Beal (Independent Non-Executive Director): Purchased 225 ADSs at $40.7649 on XNYS.
• Dr. Hal Dietz (Independent Non-Executive Director): Purchased 225 ADSs at $40.7649 on XNYS.
• Dr. Jesse Goodman (Independent Non-Executive Director): Purchased 225 ADSs at $40.7649 on XNYS.
• Dr. Jeannie Lee (Independent Non-Executive Director): Purchased 293 ADSs at $40.7649 on XNYS.
• Dr. Vishal Sikka (Independent Non-Executive Director): Purchased 1,179 ADSs at $40.7649 on XNYS.
• Emma Walmsley (Chief Executive Officer): Gifted 371,100 Ordinary Shares to family members for nil consideration (£0.00) on XLON.
• Lady Susan Symonds (PCA of Sir Jonathan Symonds): Purchased 2,000 Ordinary Shares at £16.1453 on XLON.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. It is a statutory disclosure of insider trading activity only.

Key Facts for Investor Verification

• Insider Sentiment: Multiple independent non-executive directors executed net purchases of company stock on the same day, which may signal confidence in the company's valuation.
• CEO Activity: The CEO, Emma Walmsley, transferred a significant volume of shares (371,100) as a gift to family members rather than selling them on the open market.
• Transaction Consistency: All ADS purchases were executed at the identical price of $40.7649, suggesting a coordinated or block trade execution on the NYSE.
• Reporting Limitation: This document contains no operational or financial performance data; investors must refer to Form 20-F or quarterly reports for financial metrics.